Citations

Clear

4847 citation(s) found for "Tu, Eric".

Identification of a Central DNA Flap in Feline Immunodeficiency Virus
Whitwam, Todd, Peretz, Mary, Poeschla, Eric M.

Mayo Clinic

Journal of Virology | July 27, 2002 | Volume: 75 | Issue: 19 | Pages: 9407-9414

10.1128/jvi.75.19.9407-9414.2001 | PMID 11533203 Get It

ABSTRACT A duplication of the polypurine tract (PPT) at the center of the human immunodeficiency virus type 1 (HIV-1) genome (the cPPT) has been shown to prime a separate plus-strand initiation and to result in a plus-strand displacement (DNA flap) that plays a role in nuclear import of the viral preintegration complex. Feline immunodeficiency virus (FIV) is a lentivirus that infects nondividing cells, causes progressive CD4 + T-cell depletion, and has been used as a substrate for lentiviral vectors. However, the PPT sequence is not duplicated elsewhere in the FIV genome and a central plus-strand initiation or strand displacement has not been identified. Using Southern blotting of S1 nuclease-digested FIV preintegration complexes isolated from infected cells, we detected a single-strand discontinuity at the approximate center of the reverse-transcribed genome. Primer extension analyses assigned the gap to the plus strand, and mapped the 5′ terminus of the downstream (D+) segment to a guanine residue in a purine-rich tract in pol (AAAAGAAGAGGTA G GA). RACE experiments then mapped the 3′ terminus of the upstream plus (U+)-strand segment to a T nucleotide located 88 nucleotides downstream of the D+ strand 5′ terminus, thereby identifying the extent of D+ strand displacement and the central termination sequence of this virus. Unlike HIV, the FIV cPPT is significantly divergent in sequence from its 3′ counterpart (AAAAAAGAAAAAAGGGTGG) and contains one and in some cases two pyrimidines. An invariant thymidine located −2 to the D+ strand origin is neither required nor optimal for codon usage at this position. Although the mapped cPPTs of FIV and HIV-1 act in cis , they encode homologous amino acids in integrase.
Genetic Modification of Human Trabecular Meshwork with Lentiviral Vectors
Loewen, Nils A. , Fautsch, Michael P. , Peretz, Mary, Bahler, Cindy K., Cameron, J. Douglas, Poeschla, Eric M. , Johnson, Douglas H.

Mayo Clinic

Human Gene Therapy | July 26, 2002 | Volume: 12 | Issue: 17 | Pages: 2109-2119

10.1089/10430340152677449 | PMID 11747600 Get It

Immune response of HLA-DQ8 transgenic mice to peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid arthritis.
Zanelli, Eric , Krco, Christopher J., Baisch, Jeanine , Cheng, S, David, C S, Cheng, S

Mayo Clinic

Proceedings of the National Academy of Sciences | July 26, 2002 | Volume: 93 | Issue: 5 | Pages: 1814-1819

10.1073/pnas.93.5.1814 | PMID 8700841 Get It

The major histocompatibility complex class II genes play an important role in the genetic predisposition to many autoimmune diseases. In the case of rheumatoid arthritis (RA), the human leukocyte antigen (HLA)-DRB1 locus has been implicated in the disease predisposition. The "shared epitope" hypothesis predicts that similar motifs within the third hypervariable (HV3) regions of some HLA-DRB1 alleles are responsible for the class II-associated predisposition to RA. Using a line of transgenic mice expressing the DQB1*0302/DQA1*0301 (DQ8) genes in the absence of endogenous mouse class II molecules, we have analyzed the antigenicity of peptides covering the HV3 regions of RA-associated and nonassociated DRB1 molecules. Our results show that a correlation exists between proliferative response to peptides derived from the HV3 regions of DRB1 chains and nonassociation of the corresponding alleles with RA predisposition. While HV3 peptides derived from nonassociated DRB1 molecules are highly immunogenic in DQ8 transgenic mice, all the HV3 peptides derived from RA-associated DRB1 alleles fail to induce a DQ8-restricted T-cell response. These data suggest that the role of the "shared epitope" in RA predisposition may be through the shaping of the T-cell repertoire.
Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
Reiman, Eric M. , Caselli, Richard J. , Chen, Kewei , Alexander, Gene E. , Bandy, Daniel, Frost, Jennifer

Mayo Clinic

Proceedings of the National Academy of Sciences | July 26, 2002 | Volume: 98 | Issue: 6 | Pages: 3334-3339

10.1073/pnas.061509598 | PMID 11248079 Get It

Cross-sectional positron emission tomography (PET) studies find that cognitively normal carriers of the apolipoprotein E (APOE) ɛ4 allele, a common Alzheimer's susceptibility gene, have abnormally low measurements of the cerebral metabolic rate for glucose (CMRgl) in the same regions as patients with Alzheimer's dementia. In this article, we characterize longitudinal CMRgl declines in cognitively normal ɛ4 heterozygotes, estimate the power of PET to test the efficacy of treatments to attenuate these declines in 2 years, and consider how this paradigm could be used to efficiently test the potential of candidate therapies for the prevention of Alzheimer's disease. We studied 10 cognitively normal ɛ4 heterozygotes and 15 ɛ4 noncarriers 50–63 years of age with a reported family history of Alzheimer's dementia before and after an interval of approximately 2 years. The ɛ4 heterozygotes had significant CMRgl declines in the vicinity of temporal, posterior cingulate, and prefrontal cortex, basal forebrain, parahippocampal gyrus, and thalamus, and these declines were significantly greater than those in the ɛ4 noncarriers. In testing candidate primary prevention therapies, we estimate that between 50 and 115 cognitively normal ɛ4 heterozygotes are needed per active and placebo treatment group to detect a 25% attenuation in these CMRgl declines with 80% power and P = 0.005 in 2 years. Assuming these CMRgl declines are related to the predisposition to Alzheimer's dementia, this study provides a paradigm for testing the potential of treatments to prevent the disorder without having to study thousands of research subjects or wait many years to determine whether or when treated individuals develop symptoms.
Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis -derived proteins by using HLA-transgenic, class II-deficient mice
Geluk, Annemieke , Taneja, Veena , Zanelli, Eric , Abou-Zeid, C, Thole, Jelle , Vries, René R. P. de, David, Chella S., Meijgaarden, Krista E. van , Ottenhoff, Tom H. M. , Taneja, Veena

Mayo Clinic

Proceedings of the National Academy of Sciences | July 26, 2002 | Volume: 95 | Issue: 18 | Pages: 10797-10802

10.1073/pnas.95.18.10797 | PMID 9724784 Get It

T helper 1 cells play a major role in protective immunity against mycobacterial pathogens. Since the antigen (Ag) specificity of CD4 + human T cells is strongly controlled by HLA class II polymorphism, the immunogenic potential of candidate Ags needs to be defined in the context of HLA polymorphism. We have taken advantage of class II-deficient (Ab 0 ) mice, transgenic for either HLA-DRA/B1*0301 (DR3) or HLA-DQB1*0302/DQA*0301 (DQ8) alleles. In these animals, all CD4 + T cells are restricted by the HLA molecule. We reported previously that human DR3-restricted T cells frequently recognize heat shock protein (hsp)65 of Mycobacterium tuberculosis , and only a single hsp65 epitope, p1–20. DR3.Ab 0 mice, immunized with bacillus Calmette–Guérin or hsp65, developed T cell responses to M. tuberculosis , and recognized the same hsp65 epitope, p1–20. Hsp65-immunized DQ8.Ab 0 mice mounted a strong response to bacillus Calmette–Guérin but not to p1–20. Instead, we identified three new DQ8-restricted T cell epitopes in the regions 171–200, 311–340, and 411–440. DR3.Ab 0 mice immunized with a second major M. tuberculosis protein, Ag85 (composed of 85A, 85B, and 85C), also developed T cell responses against only one determinant, 85B p51–70, that was identified in this study. Importantly, subsequent analysis of human T cell responses revealed that HLA-DR3+, Ag85-reactive individuals recognize exactly the same peptide epitope as DR3.Ab 0 mice. Strikingly, both DR3-restricted T cell epitopes represent the best DR3-binding sequences in hsp65 and 85B, revealing a strong association between peptide-immunodominance and HLA binding affinity. Immunization of DR3.Ab 0 with the immunodominant peptides p1–20 and p51–70 induced T cell reactivity to M. tuberculosis . Thus, for two different Ags, T cells from DR3.Ab 0 mice and HLA-DR3+ humans recognize the same immunodominant determinants. Our data support the use of HLA-transgenic mice in identifying human T cell determinants for the design of new vaccines.
In Vivo Expression of a Variant Human U6 RNA from a Unique, Internal Promoter
Tichelaar, Jay W., Wieben, Eric D. , Reddy, Ram, Vrabel, Anne M., Camacho, Patricia

Mayo Clinic

Biochemistry | July 26, 2002 | Volume: 37 | Issue: 37 | Pages: 12943-12951

10.1021/bi9811361 | PMID 9737874 Get It

Clinicopathologic Study of Ectomesenchymomas from Intergroup Rhabdomyosarcoma Study Groups III and IV
Boué, Daniel R. , Parham, David M. , Crist, William M., Qualman, Stephen J., Office, from the Intergroup Rhabdomyosarcoma Study Group (IRSG) representing the Children's Cancer Group, the Pediatric Oncology Group,, Anderson, James R., Breitfeld, Richard J., Breneman, John C. , Bridge, Julia A. , Brown, Kenneth L. , Grier, Holcombe E. , Houghton, Peter J. , Link, Michael P., Lobe, Thom L., Maurer, Harold M., Meyer, William H. , Michalski, Jeff M. , Murphy, Sharon, Raney, R. Beverly, Robison, Leslie, Skapek, Stephen X. , Teot, Lisa A., Vietti, Teresa J., Walterhouse, David , Wharam, Mondy, Wiener, Eugene S. , Womer, Richard B. , Webber, Bruce L. , Office, from the Intergroup Rhabdomyosarcoma Study Group (IRSG) representing the Children's Cancer Group, the Pediatric Oncology Group, and the Intergroup Rhabdomyosarcoma Statistical, Anderson, James R., Donaldson, Sarah S. , Hawkins, Douglas S. , Paidas, Charles N. , Pappo, Alberto S. , Sandler, Eric , Smith, Lynn , Sorensen, Poul H. , Spunt, Sheri L. , Triche, Timothy J. , Wolden, Suzanne L.

Mayo Clinic

Pediatric and Developmental Pathology | July 25, 2002 | Volume: 3 | Issue: 3 | Pages: 290-300

10.1007/s100249910039 | PMID 10742419 Get It

Ectomesenchymomas (EM) are rare malignant neoplasms usually consisting of rhabdomyosarcoma (RMS) with a neural component. Only 21 cases have been previously reported. Here we extend the clinicopathologic spectrum of EM by describing our findings in 15 cases. Only 5 patients were infants; 10 were ≤3 years old and 5 were ≥6 years old. No male predilection was observed; 7 were female. The originating institutional diagnoses were; RMS (12), undifferentiated sarcoma (1), or EM (2), suggesting underdiagnosis of this entity. The primary tumor sites included external genital (5), pelvis/abdomen (6), head and neck (3), and extremity (1). The size of the primary neoplasm was usually ≥5 cm at diagnosis but dissemination only occurred in a minority. Local infiltration was not uncommon. These neoplasms were typically multilobate, thinly encapsulated, hemorrhagic, and necrotic. Light microscopic features were highly variable, but embryonal RMS with scattered or clustered ganglion cells, often in lacunae, was characteristic. In some cases, primitive neuroblastic or neuroectodermal areas were found and/or a component of alveolar RMS was seen. Focal anaplasia was occasionally observed. Mitotic activity appears higher than previously appreciated and some necrosis was invariably present. Electron microscopy was performed in 11 cases, which confirmed skeletal muscle ± neural differentiation. Cytogenetic studies performed in five cases revealed no specific abnormality. Monoclonal neuron-specific enolase was the best marker of ganglion cells and primitive neural elements. MIC-2 (CD99) membrane expression was not definitively present in any of the six cases examined. A number of the above parameters appear to be of some prognostic significance, but overall, these neoplasms appear to have a similar outcome as would be predicted for their RMS element alone (exclusive of any neural component), with respect to the RMS subtype, age of the patient, and anatomic location of the neoplasm.